Cargando…
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
There are unmet needs for pharmacologic agents beyond current medications, such as statins, to effectively lower low-density lipoprotein cholesterol levels to target goals, especially in patients with very high or extremely high risk. Pharmacological targeting of mRNA represents an emerging, innovat...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society of Lipidology and Atherosclerosis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515732/ https://www.ncbi.nlm.nih.gov/pubmed/36212748 http://dx.doi.org/10.12997/jla.2022.11.3.250 |